Esprolol

Esprolol
Clinical data
Other names(S)-ACC-9369; (S)-ACC9369
Routes of
administration		Sublingual
Drug classBeta blocker; β1-Adrenergic receptor antagonist
ATC code
  • None
Pharmacokinetic data
MetabolismEsterases
MetabolitesAmoxolol
Onset of action"Rapid"
Duration of action"Short"
Identifiers
  • ethyl 3-[2-[(2S)-2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanoate
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC17H27NO4
Molar mass309.406 g·mol−1
3D model (JSmol)
  • CCOC(=O)CCC1=CC=CC=C1OC[C@H](CNC(C)C)O
  • InChI=1S/C17H27NO4/c1-4-21-17(20)10-9-14-7-5-6-8-16(14)22-12-15(19)11-18-13(2)3/h5-8,13,15,18-19H,4,9-12H2,1-3H3/t15-/m0/s1
  • Key:DMLSVZSUDBKLED-HNNXBMFYSA-N

Esprolol, also known as (S)-ACC-9369, is a beta blocker which was under development for the treatment of angina pectoris, anxiety disorders, and migraine. It is taken sublingually and has a rapid onset of action, short time to peak, and short duration. The drug is a prodrug of amoxolol, which is formed from esprolol via esterase enzymes. It is a selective β1-adrenergic receptor antagonist. Esprolol was under development by Selectus Pharmaceuticals. It reached phase 2 clinical trials for all indications prior to the discontinuation of its development in 2001.

See also

References

  1. 1 2 3 4 5 6 "Esprolol". AdisInsight. 25 June 2001. Retrieved 5 June 2026.
  2. 1 2 3 4 5 6 7 8 9 Matier WL, Patil G (2000). "Esprolol hydrochloride: a new beta adrenergic antagonist with a rapid onset of effect". Heart Dis. 2 (2): 146–150. PMID 11728252.
  3. 1 2 3 "Delving into the Latest Updates on Esprolol Hydrochloride with Synapse". Synapse. 30 May 2026. Retrieved 5 June 2026.
  4. ↑ Frishman WH, Alwarshetty M (2002). "Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines". Clin Pharmacokinet. 41 (7): 505–516. doi:10.2165/00003088-200241070-00004. PMID 12083978. A sublingual β1-selective blocker, esprolol, is now being evaluated in clinical trials.[30]